Background and Aims: Studies have shown an increased incidence of chronic complications in people with type 1 diabetes mellitus (T1DM) with insulin resistance (IR) compared to people with T1DM without IR. Estimated glucose disposal rate (eGDR) is an important indicator of IR in patients with T1DM, lower eGDR levels indicating greater IR. It was shown that T1DM patients with chronic complications (diabetic retinopathy - DR, diabetic peripheral neuropathy - DPN or diabetic kidney disease - DKD) exhibit higher IR compared to patients without chronic complications. The aim of our study was to evaluate eGDR as a marker for the assessment of IR in T1DM patients.
Materials and Methods: The study was observational, cross-sectional and included 140 T1DM patients with diabetes duration>10 years. The collected data were analyzed using the Statistic Package for Social Sciences (SPSS) version 22 software (IBM Corporation, Armonk, NY, USA).
Results: eGDR presented statistically significant correlations (p<0.05) with the presence of metabolic syndrome (MS), obesity, chronic complications of T1DM, cardiovascular risk (CVR) and smoking status in patients with T1DM duration >10 years.
Conclusions: eGDR represents a reliable marker for assessing the IR in T1DM.
1. Chillarón JJ, Goday A, Flores-Le-Roux JA et al. Estimated glucose disposal rate in assessment of the metabolic syndrome and microvascular complications in patients with type 1 diabetes. J Clin Endocrinol Metab 94: 3530-3534, 2009.
2. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49: 626-632, 2000.
3. Danielson KK, Drum ML, Estrada CL, Lipton RB. Racial and ethnic differences in an estimated measure of insulin resistance among individuals with type 1 diabetes. Diabetes Care 33: 614-619, 2010.
4. Pambianco G, Costacou T, Orchard TJ. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30: 1248-1254, 2007.
5. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care 30: 707-712, 2007.
6. Dincă M. Dislipidemiile şi aterogeneza. In: Patologia nutriţional metabolicǎ. Moţa M, Dincǎ M (ed.). Publisher Medical University, Craiova, pp 53-84, 2010.
7. Park CW. Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J 38: 252-260, 2014.
8. American Diabetes Association. Microvascular complications and foot care. Sec. 9. In: Standards of Medical Care in Diabetes 2015. Diabetes Care 38(Suppl.1): S58-S66, 2015.
9. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 121(1 Pt 2): 293-298, 1991.
10. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645, 2009.
11. Niţă C, Hâncu N. Identificarea şi diagnosticul factorilor de risc, evaluarea riscului cardiovascular, stabilirea obiectivelor managementului clinic. In: Riscul cardiovascular în diabetul zaharat. Niţă C, Hâncu N (ed). Echinox Publisher, Cluj Napoca, pp 45-78, 2008.
12. Epstein EJ, Osman JL, Cohen HW, Rajpathak SN, Lewis O, Crandall JP. Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. Diabetes Care 36: 2280-2285, 2013.